Traws Pharma Inc (TRAW)

Market Cap	16.00M
Revenue (ttm)	226,000
Net Income (ttm)	-18.95M
Shares Out	25.30M
EPS (ttm)	-0.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,158
Open	0.630
Previous Close	0.640
Day's Range	0.630 - 0.650
52-Week Range	0.550 - 1.450
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 16, 2024

About TRAW

Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-smal...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 25, 2013
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: TRAW

Financial Performance

In 2023, Traws Pharma's revenue was $226,000, a change of 0.00% compared to the previous year's $226,000. Losses were -$18.95 million, -0.08% less than in 2022.

Financial numbers in USD